软组织肉瘤的医疗保险优势可能与更糟糕的患者结果有关
Jennifer C Wang1, Kevin C Liu1, Brandon S Gettleman2
1Department of Orthopaedic Surgery, Keck School of Medicine of the University of Southern California, Los Angeles, CA 90033, USA.
Journal of clinical medicine
|August 12, 2023
概括
这项研究发现,在接受下肢软组织肉瘤 (STS) 切除的患者的术后结果没有显著差异,比较传统的医疗保险 (TM) 和医疗保险优势 (MA) 计划. 由于研究的潜在局限性,需要进一步的研究来证实这些发现.
科学领域:
- 在瘤学瘤学.
- 医疗保健服务研究 医疗服务研究
- 外科手术的结果
背景情况:
- 与传统医疗保险 (TM) 相比,Medicare Advantage (MA) 计划可能会引入影响患者结果的障碍.
- 下肢软组织肉瘤 (STS) 切除是一个重要的手术程序,有可能导致术后并发症.
研究的目的:
- 为了比较90天的术后结果,在TM计划和MA计划中接受下肢STS切除的患者.
- 根据医疗保险覆盖类型,确定手术结果的潜在差异.
主要方法:
- 对于65岁以上的患者进行下肢STS切除的Premier Healthcare数据库 (2015-2021) 的回顾性分析.
- 在TM和MA队列之间比较患者特征,并发症和住院因素.
- 双变量和多变量分析以评估90天的术后并发症风险,控制混因素.
主要成果:
- 包括1858名患者,595人 (32.0%) 患有MA,1048人 (56.4%) 患有TM覆盖.
- 在MA患者中,外周血管疾病和甲状腺功能低下的频率较高.
- 多变量分析显示,在MA队列中,肺栓塞,中风,手术部位感染和90天住院死亡的几率较高,但这些趋势没有达到统计学意义.
结论:
- 这项研究没有发现TM和MA患者进行下肢STS切除后的术后结果在统计学上有显著差异.
- 潜在的不足或缺乏瘤因素控制可能解释非显著的发现.
- 需要大型的多机构研究来最终评估STS切除患者的Medicare亚型的结果差异.
更多相关视频
相关概念视频
01:21Cancer Survival Analysis
384
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
384
01:24Kaplan-Meier Approach
180
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
180
02:56Treatment Resistant Cancers
3.3K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.3K